Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson Sells 6,256 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 6,256 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the sale, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, October 3rd, Travis Alvin Thompson sold 153 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $22.26, for a total transaction of $3,405.78.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $23.22 on Thursday. The stock has a market cap of $1.10 billion, a P/E ratio of -7.06 and a beta of 0.89. Bicycle Therapeutics plc has a fifty-two week low of $13.07 and a fifty-two week high of $28.67. The firm’s fifty day moving average price is $24.55 and its 200-day moving average price is $23.18.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The firm had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company’s revenue for the quarter was down 50.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) EPS. On average, analysts predict that Bicycle Therapeutics plc will post -3.01 earnings per share for the current year.

Institutional Trading of Bicycle Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Assetmark Inc. purchased a new stake in Bicycle Therapeutics during the third quarter valued at about $34,000. GAMMA Investing LLC boosted its holdings in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after acquiring an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after acquiring an additional 2,918 shares during the period. XTX Topco Ltd bought a new position in Bicycle Therapeutics during the 2nd quarter worth approximately $206,000. Finally, Crossmark Global Holdings Inc. purchased a new position in Bicycle Therapeutics in the 3rd quarter worth approximately $257,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating and issued a $48.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Stephens initiated coverage on shares of Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.13.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.